Evolus, Inc. (EOLS)
6.71
+0.08
(+1.21%)
USD |
NASDAQ |
Nov 17, 16:00
6.77
+0.06
(+0.89%)
After-Hours: 20:00
Evolus Total Liabilities (Quarterly) : 321.64M for Sept. 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 321.64M |
| June 30, 2026 | 278.93M |
| March 31, 2026 | 249.43M |
| December 31, 2025 | 248.97M |
| September 30, 2025 | 247.76M |
| June 30, 2025 | 247.46M |
| March 31, 2025 | 219.96M |
| December 31, 2024 | 227.05M |
| September 30, 2024 | 223.72M |
| June 30, 2024 | 214.46M |
| March 31, 2024 | 207.73M |
| December 31, 2023 | 209.69M |
| September 30, 2023 | 187.34M |
| June 30, 2023 | 175.95M |
| March 31, 2023 | 153.29M |
| December 31, 2022 | 159.48M |
| September 30, 2022 | 163.50M |
| June 30, 2022 | 164.06M |
| March 31, 2022 | 153.41M |
| December 31, 2021 | 175.61M |
| Date | Value |
|---|---|
| September 30, 2021 | 117.82M |
| June 30, 2021 | 133.72M |
| March 31, 2021 | 133.91M |
| December 31, 2020 | 282.03M |
| September 30, 2020 | 180.68M |
| June 30, 2020 | 150.94M |
| March 31, 2020 | 151.54M |
| December 31, 2019 | 160.98M |
| September 30, 2019 | 165.62M |
| June 30, 2019 | 161.60M |
| March 31, 2019 | 145.57M |
| December 31, 2018 | 87.46M |
| September 30, 2018 | 88.41M |
| June 30, 2018 | 84.00M |
| March 31, 2018 | 75.41M |
| December 31, 2017 | 227.78M |
| September 30, 2017 | 229.46M |
| June 30, 2017 | 213.14M |
| March 31, 2017 | |
| December 31, 2016 | 84.60M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 930.55M |
| Corcept Therapeutics, Inc. | 200.29M |
| Veru, Inc. | 8.651M |
| Johnson & Johnson | 115.90B |
| Eli Lilly & Co. | 107.80B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 283.82M |
| Shareholders Equity (Quarterly) | -37.81M |
| Debt to Equity Ratio | -4.379 |
| Current Ratio | 1.417 |
| Net Debt Paydown Yield | -0.40% |